☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - February 2014

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Colestilan (BindRen®) has been rejected for the treatment of hyperphosphataemia in adult patients with chronic kidney disease (CKD) stage 5 receiving haemodialysis or peritoneal dialysis. The clinical and economic analysis was not sufficiently robust to gain acceptance but a resubmission is expected.

Levonorgestrel (Upostelle®) has been accepted for use as emergency contraception within 72 hours of unprotected sexual intercourse or failure of a contraceptive method. The review notes that this product is a slightly cheaper alternative to an existing preparation.

Lomitapide (Lojuxta®) has been rejected for use as an adjunct to a low-fat diet and other lipid-lowering medicinal products, with or without low density lipoprotein (LDL) apheresis, in adult patients with homozygous familial hypercholesterolaemia (HoFH). The manufacturer failed to make a submission.

Timolol gel eye drops (Tiopex®) have been accepted for restricted for the reduction of the elevated intraocular pressure in patients with ocular hypertension or chronic open angle glaucoma. The restriction limits use to patients who have proven sensitivity to preservatives.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - February 2014' by emailShare 'SMC Update - February 2014' on FacebookShare 'SMC Update - February 2014' on TwitterShare 'SMC Update - February 2014' on LinkedInShare 'SMC Update - February 2014' on reddit


No Comments to “SMC Update - February 2014”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.